Brentuximab vedotin effective in large-cell lymphoma

May 24, 2012
Brentuximab vedotin effective in large-Cell lymphoma

(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, according to the results of a phase II study published online May 21 in the Journal of Clinical Oncology.

Barbara Pro, M.D., of the Fox Chase Cancer Center in Philadelphia, and colleagues conducted a prospective study involving 58 patients with systemic ALCL and after at least one previous therapy. Participants received an outpatient infusion of brentuximab vedotin 1.8 mg/kg every three weeks. Overall objective response rate was the primary study end point.

The researchers found that 86, 57, and 29 percent of patients achieved an objective response, a complete remission (CR), and a partial remission, respectively. The median duration was 12.6 months for overall response and 13.2 months for CR. The most common grade 3 or 4 adverse events were , , and peripheral sensory neuropathy.

"Brentuximab vedotin induced objective responses in the majority of patients and CRs in more than half of patients with recurrent systemic ALCL," the authors write. "Targeted therapy with this CD30-directed antibody-drug conjugate may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy."

Several authors disclosed financial ties to Seattle Genetics, which funded the study and manufactures brentuximab vedotin.

Explore further: Chemo combination promising for multiple myeloma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Novel experimental agent is highly active in CLL patients, interim study shows

December 11, 2011
An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...

Children with cancer have complete responses in a Children's Oncology Group phase 1 trial

May 17, 2012
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.

Regorafenib active in metastatic GI stromal tumors

May 23, 2012
(HealthDay) -- Regorafenib, an inhibitor of multiple cancer-associated kinases, is active in patients with metastatic gastrointestinal stromal tumors (GIST) who have failed to respond to imatinib and sunitinib, according ...

Novel experimental agent is highly active in CLL patients, interim study shows

June 6, 2011
An interim analysis of a phase II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated both in patients who are undergoing treatment for the first ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.